ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Administration to Request 3.9% Increase for NIH; 1.3% Raise For NCI In FY97

March 8, 1996

NCI Considers Seeking New Study Section For Clinical Research, Or Expansion Of E2

November 23, 1990

How NCI Plans to Spend the $3 Billion Budget; But First, A Caveat From the Director

November 19, 1999

“Action Steps” Listed For Prostate Research In National Blueprint

January 16, 1998

In Brief: NCAB To Hear NCI Staff Plans For Implementing Recommendation On Nutrition & Cancer Task Force

October 1, 1982

In Brief: Breast Cancer Coalition Seeks Survivors, Activists For 3-Day Course In Advocacy

April 28, 1995